Overview

Reparixin as add-on Therapy to Standard of Care to Limit Disease Progression in Adult Patients With COVID-19.

Status:
Not yet recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
Primary objective: - To evaluate the efficacy of oral reparixin versus standard care alone in limiting disease progression in adult patients hospitalised for COVID-19. Secondary objectives: - To determine the effect of reparixin on several disease severity/progression measures including recovery, ventilatory free days and mortality. Safety objectives: - To evaluate the safety of oral reparixin versus placebo in the specific clinical setting.
Phase:
Phase 3
Details
Lead Sponsor:
Dompé Farmaceutici S.p.A